2019 Expert opinion on biological treatment use in inflammatory bowel disease management
- 15 April 2019
- journal article
- research article
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
- Vol. 30 (Supplement) , S913-S944
Abstract
Cite this article as: Törüner M, Akpınar H, Akyüz F, et al. 2019 Expert opinion on biological treatment use in inflammatory bowel disease management. Turk J Gastroenterol 2019; 30(Suppl 4): S913-46.Keywords
This publication has 213 references indexed in Scilit:
- Placental Transfer of Anti–Tumor Necrosis Factor Agents in Pregnant Patients With Inflammatory Bowel DiseaseClinical Gastroenterology and Hepatology, 2013
- Serious Infection and Mortality in Patients With Crohn's Disease: More Than 5 Years of Follow-Up in the TREAT™ RegistryAmerican Journal of Gastroenterology, 2012
- Corticosteroid use during pregnancy and risk of orofacial cleftsCanadian Medical Association Journal, 2011
- Tumour necrosis factor-alpha expression in tumour islets confers a survival advantage in non-small cell lung cancerBMC Cancer, 2010
- Infliximab, Azathioprine, or Combination Therapy for Crohn's DiseaseNew England Journal of Medicine, 2010
- Risk of Lymphoma Associated With Combination Anti–Tumor Necrosis Factor and Immunomodulator Therapy for the Treatment of Crohn's Disease: A Meta-AnalysisClinical Gastroenterology and Hepatology, 2009
- Meta‐analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitisAlimentary Pharmacology & Therapeutics, 2009
- Immunosuppressive Therapy and Malignancy in Organ Transplant RecipientsDrugs, 2007
- A meta-analysis on the influence of inflammatory bowel disease on pregnancyGut, 2006
- Infliximab for the Treatment of Fistulas in Patients with Crohn's DiseaseNew England Journal of Medicine, 1999